Hospital

A large cohort study found that urate-lowering therapy was associated with a reduction in risk for composite kidney outcomes in patients with stage 3 or higher chronic kidney disease (CKD) and hyperuricemia.

Capivasertib plus abiraterone improves survival in PTEN-deficient hormone-sensitive prostate cancer.

PEACE-3 trial data presented at ASCO GU show survival benefits with enzalutamide combination.

Learn how COVID-19 drives heart and vascular risks, why vaccines and antivirals help, and how pharmacists manage dangerous drug interactions.

Awareness of the nonlinear response helps ensure patients are treated with the least intensive regimen that achieves meaningful control while minimizing harm and improving long-term therapeutic success.

Managing high-cost oncology therapies requires extensive cross-functional coordination, with pharmacists playing a central role.

Comprehensive prevention and cardiometabolic risk control in prediabetes can reduce long-term complications, improve survival, and lower health system burden.

The approval for the oral, fixed-duration chronic lymphocytic leukemia (CLL) regimen was based on results from the phase 3 AMPLIFY trial.

A new 4-pillar framework blends AI, real-time PDMP data, and social determinants of health to spot opioid misuse earlier and reduce overdoses.

FDA approves encorafenib plus cetuximab chemotherapy for BRAF V600E metastatic colorectal cancer, boosting survival and response in BREAKWATER.

FDA clears pegzilarginase-nbln enzyme therapy for ARG1-D, cutting toxic arginine and boosting mobility.

HER2 breast cancer vaccine boosted by CD27 sparked durable CD4 memory and dramatic tumor regression in studies.

Study authors suggest that VA and health care professionals should educate patients on the medical evidence, gaps, policies, and laws related to cannabis.

The guideline establishes a novel clinical classification framework and recommends direct oral anticoagulants over vitamin K antagonists for eligible patients.

Experts Craig Beavers and Kristen Campbell discuss what pharmacists should know heading into ACC 26.

Oncology pharmacists discuss the transformative role of bispecific antibodies in treating relapsed/refractory multiple myeloma, addressing challenges and patient care strategies.

Why smarter supply chain management protects patients and pharmacy operations

Preventing progression from prediabetes to type 2 diabetes improves patient outcomes while substantially reducing health system greenhouse gas emissions.

The authors urge air quality interventions to promote and support dementia prevention strategies.

Fluid therapy in pediatrics involves a systematic approach distinguishing maintenance, deficit, and replacement fluids to effectively manage hydration and electrolyte balance.

Frontline therapy for DLBCL is evolving with the integration of targeted and cellular therapies, demonstrating promising outcomes.

A multicohort analysis reveals that obesity substantially increases hospitalization and mortality risk across diverse infectious diseases.

Pembrolizumab in adjuvant NSCLC therapy can trigger central adrenal insufficiency with vague fatigue, nausea, and hyponatremia.

A pressure vibration device can cut propofol injection pain in patients undergoing surgeries, matching low-dose ketamine without extra adverse events.

Craig Beavers, PharmD, explores new phase 3 evidence on factor XIa inhibitors for secondary stroke prevention, highlighting OCEANIC-STROKE results, safety, and patient selection.

The biosimilar is a cost-effective treatment for patients with conditions caused by cancer treatment.

Joseph Saseen, PharmD, explains how population health strategies and team-based care create new opportunities for pharmacists to identify lipid treatment gaps and lead evidence-based ASCVD prevention.

Telehealth expands physical therapy and pharmacy support.